sb 239063 has been researched along with Insulin Resistance in 1 studies
SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pereira, S | 1 |
| Yu, WQ | 1 |
| Moore, J | 1 |
| Mori, Y | 1 |
| Tsiani, E | 1 |
| Giacca, A | 1 |
1 other study available for sb 239063 and Insulin Resistance
| Article | Year |
|---|---|
Effect of a p38 MAPK inhibitor on FFA-induced hepatic insulin resistance in vivo.
Topics: Activating Transcription Factor 2; Animals; Blood Glucose; Emulsions; Enzyme Inhibitors; Fatty Acids | 2016 |